Off-label uses of quetiapine Review article
Article Sidebar
Published:
Mar 31, 2013
Keywords:
quetiapine, off-label use
Main Article Content
Abstract
The atypical antipsychotic quetiapine, which is approved for schizophrenia, bipolar disorder, and refractory major depression, is extensively being used off-label. Quetiapine is commonly prescribed for major depression (unipolar), anxiety, insomnia, aggression, agitation, disruptive disorders, borderline personality disorder, alcohol dependence, and for behavioural and psychological symptoms of dementia. This article reviews the off-label prescription of quetiapine in the treatment of a broad range of psychiatric disorders.
Article Details
Issue
Section
Articles
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright: © Medical Education sp. z o.o. License allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
1. Maglione M, Maher AR, Hu J, Wang Z, Shanman R, Shekelle PG, Roth B, Hilton L, Suttorp MJ, Ewing BA, Motala A, Perry T. Off-Label Use of Atypical Antipsychotics: An Update. Comparative Effectiveness Reviews, No. 43. Agency for Healthcare Research and Quality; Rockville (MD) 2011.
2. Walton SM, Schumack GT, Ky-Van L, Alexander GC, Meltzer D, Stafford R. Developing evidence-based research priorities for off-label drug use. Agency for Healthcare Research and Quality, Rockville, MD, 2009.
3. Bauer M et al. Results from a phase III study of extended release quetiapine fumarate (quetiapine XR) as add-on to antidepressants in patients with major depressive disorder (MDD). International Forum on Mood and Anxiety Disorders, Budapeszt, Węgry, 5–7 grudnia 2007.
4. Montgomery S et al. A randomised, placebo-controlled study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder (MDD). International Forum on Mood and Anxiety Disorders, Budapeszt, Węgry, 5–7 grudnia 2007.
5. Katzman MA, Brawman-Mintzer O, Reyes EB, Olausson B, Liu S, Eriksson H. Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: a long-term, randomized, placebo- controlled trial. Int Clin Psychopharmacol 2011; 26(1): 11-24.
6. Khan A, Joyce M, Atkinson S, Eggens I, Baldytcheva I, Eriksson H. A randomized, double-blind study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder. J Clin Psychopharmacol 2011; 31(4): 418-428.
7. Buna M. Pozarejestracyjne zastosowanie kwetiapiny w leczeniu bezsenności. Neuropsychiatria. Przegląd Kliniczny 2012; 4(4): 178-181.
8. Łoza B, Parnowski T. Nowa depresja. Nowe leczenie. Medical Education, Warszawa 2012, wydanie I.
9. Lydiard RB, Culpepper L, Schiöler H, Gustafsson U, Paulsson B. Quetiapine Monotherapy as Treatment for Anxiety Symptoms in Patients With Bipolar Depression: A Pooled Analysis of Results From 2 Double-Blind, Randomized, Placebo-Controlled Studies. Prim Care Companion J Clin Psychiatry 2009; 11(5): 215-225.
10. Pasquini M, Speca A, Biondi M. Quetiapine for tamoxifen-induced insomnia in women with breast cancer. Psychosomatics 2009; 50(2): 159-161.
11. Schutte-Rodin S, Broch L, Buysse D, Dorsey C, Sateia M. Clinical Guideline for the Evaluation and Management of Chronic Insomnia in Adults. J Clin Sleep Med 2008; 4(5): 487-504.
12. Coe HV, Hong IS. Safety of low doses of quetiapine when used for insomnia. Ann Pharmacother 2012; 46(5): 718-722.
13. Gedge L, Lazowski L, Murray D, Jokic R, Milev R. Effects of quetiapine on sleep architecture in patients with unipolar or bipolar depression. Neuropsychiatr Dis Treat 2010; 6: 501-508.
14. Baune BT, Caliskan S, Todder D. Effects of adjunctive antidepressant therapy with quetiapine on clinical outcome, quality of sleep and daytime motor activity in patients with treatment- resistant depression. Hum Psychopharmacol 2007; 22(1): 1-9.
15. Kozma CM, Engelhart LM, Long S, Greenspan A, Mahmoud R, Baser O. Absence of increased relative stroke risk in elderly dementia patients treated with risperidone versus other antipsychotics. International College of Geriatric Psychoneuropharmacology 2003.
16. Powers RE. A Short Practical Guide for Psychotropic Medications in Dementia Patients. Bureau of Geriatric Psychiatry, Alabama 2008.
17. Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, DeKosky S. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA 2002; 288(12): 1475-1483.
18. Dolder CR, McKinsey J. Quetiapine for sleep in patients with dementia. Consult Pharm 2010; 25(10): 676-679.
19. Zhong KX, Tariot PN, Mintzer J, Minkwitz MC, Devine NA. Quetiapine to treat agitation in dementia: a randomized, doubleblind, placebo-controlled study. Curr Alzheimer Res 2007; 4(1): 81-93.
20. Golubchik P, Sever J, Weizman A. Low-dose quetiapine for adolescents with autistic spectrum disorder and aggressive behavior: open-label trial. Clin Neuropharmacol 2011; 34(6): 216-219.
21. Mukaddes NM, Abali O. Quetiapine treatment of children and adolescents with Tourette’s disorder. J Ch Adol Psychopharm 2003; 13(3): 295-299.
22. Van den Eynde F, De Saedeleer S, Naudts K, Day J, Vogels C, van Heeringen C, Audenaert K. Quetiapine treatment and improved cognitive functioning in borderline personality disorder. Hum Psychopharmacol 2009; 24(8): 646-649.
23. Van den Eynde F, Senturk V, Naudts K, Vogels C, Bernagie K, Thas O, van Heeringen C, Audenaert K. Efficacy of quetiapine for impulsivity and affective symptoms in borderline personality disorder. J Clin Psychopharmacol 2008; 28(2): 147-155.
24. Adityanjee A, Romine A, Brown E, Thuras P, Lee S, Schulz SC. Quetiapine in patients with borderline personality disorder: an open-label trial. Ann Clin Psychiatry 2008; 20(4): 219-226.
25. Perrella C, Carrus D, Costa E, Schifano F. Quetiapine for the treatment of borderline personality disorder; an open-label study. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31(1): 158-163.
26. Roepke S, Merkl A, Dams A, Ziegenhorn A, Anghelescu IG, Heuser I, Lammers CH. Preliminary evidence of improvement of depressive symptoms but not impulsivity in cluster B personality disorder patients treated with quetiapine: an open label trial. Pharmacopsychiatry 2008; 41(5): 176-181.
27. Rihmer Z. Antidepressive efficacy of quetiapine XR in unipolar major depression – the role of early onset of action and sleepimproving effect in decreasing suicide risk. Neuropsychopharmacol Hung 2009; 11(4): 211-215.
28. Stedman M, Pettinati HM, Brown ES, Kotz M, Calabrese JR, Raines S. A double-blind, placebo-controlled study with quetiapine as adjunct therapy with lithium or divalproex in bipolar I patients with coexisting alcohol dependence. Alcohol Clin Exp Res 2010; 34(10): 1822-1831.
29. Litten RZ, Fertig JB, Falk DE, Ryan ML, Mattson ME, Collins JF, Murtaugh C, Ciraulo D, Green AI, Johnson B, Pettinati H, Swift R, Afshar M, Brunette MF, Tiouririne NA, Kampman K, Stout R. A double-blind, placebo-controlled trial to assess the efficacy of quetiapine fumarate XR in very heavy-drinking alcohol-dependent patients. Alcohol Clin Exp Res 2012; 36(3): 406-416.
30. Cooper ZD, Foltin RW, Hart CL, Vosburg SK, Comer SD, Haney M. A human laboratory study investigating the effects of quetiapine on marijuana withdrawal and relapse in daily marijuana smokers. Addict Biol 2012 Jun 28 [doi: 10.1111/j.1369-1600.2012.00461.x].
31. Kampman KM, Pettinati HM, Lynch KG, Whittingham T, Macfadden W, Dackis C, Tirado C, Oslin DW, Sparkman T, O’Brien CP. A double-blind, placebo-controlled pilot trial of quetiapine for the treatment of Type A and Type B alcoholism. J Clin Psychopharmacol 2007; 27(4): 344-351.
2. Walton SM, Schumack GT, Ky-Van L, Alexander GC, Meltzer D, Stafford R. Developing evidence-based research priorities for off-label drug use. Agency for Healthcare Research and Quality, Rockville, MD, 2009.
3. Bauer M et al. Results from a phase III study of extended release quetiapine fumarate (quetiapine XR) as add-on to antidepressants in patients with major depressive disorder (MDD). International Forum on Mood and Anxiety Disorders, Budapeszt, Węgry, 5–7 grudnia 2007.
4. Montgomery S et al. A randomised, placebo-controlled study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder (MDD). International Forum on Mood and Anxiety Disorders, Budapeszt, Węgry, 5–7 grudnia 2007.
5. Katzman MA, Brawman-Mintzer O, Reyes EB, Olausson B, Liu S, Eriksson H. Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: a long-term, randomized, placebo- controlled trial. Int Clin Psychopharmacol 2011; 26(1): 11-24.
6. Khan A, Joyce M, Atkinson S, Eggens I, Baldytcheva I, Eriksson H. A randomized, double-blind study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder. J Clin Psychopharmacol 2011; 31(4): 418-428.
7. Buna M. Pozarejestracyjne zastosowanie kwetiapiny w leczeniu bezsenności. Neuropsychiatria. Przegląd Kliniczny 2012; 4(4): 178-181.
8. Łoza B, Parnowski T. Nowa depresja. Nowe leczenie. Medical Education, Warszawa 2012, wydanie I.
9. Lydiard RB, Culpepper L, Schiöler H, Gustafsson U, Paulsson B. Quetiapine Monotherapy as Treatment for Anxiety Symptoms in Patients With Bipolar Depression: A Pooled Analysis of Results From 2 Double-Blind, Randomized, Placebo-Controlled Studies. Prim Care Companion J Clin Psychiatry 2009; 11(5): 215-225.
10. Pasquini M, Speca A, Biondi M. Quetiapine for tamoxifen-induced insomnia in women with breast cancer. Psychosomatics 2009; 50(2): 159-161.
11. Schutte-Rodin S, Broch L, Buysse D, Dorsey C, Sateia M. Clinical Guideline for the Evaluation and Management of Chronic Insomnia in Adults. J Clin Sleep Med 2008; 4(5): 487-504.
12. Coe HV, Hong IS. Safety of low doses of quetiapine when used for insomnia. Ann Pharmacother 2012; 46(5): 718-722.
13. Gedge L, Lazowski L, Murray D, Jokic R, Milev R. Effects of quetiapine on sleep architecture in patients with unipolar or bipolar depression. Neuropsychiatr Dis Treat 2010; 6: 501-508.
14. Baune BT, Caliskan S, Todder D. Effects of adjunctive antidepressant therapy with quetiapine on clinical outcome, quality of sleep and daytime motor activity in patients with treatment- resistant depression. Hum Psychopharmacol 2007; 22(1): 1-9.
15. Kozma CM, Engelhart LM, Long S, Greenspan A, Mahmoud R, Baser O. Absence of increased relative stroke risk in elderly dementia patients treated with risperidone versus other antipsychotics. International College of Geriatric Psychoneuropharmacology 2003.
16. Powers RE. A Short Practical Guide for Psychotropic Medications in Dementia Patients. Bureau of Geriatric Psychiatry, Alabama 2008.
17. Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, DeKosky S. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA 2002; 288(12): 1475-1483.
18. Dolder CR, McKinsey J. Quetiapine for sleep in patients with dementia. Consult Pharm 2010; 25(10): 676-679.
19. Zhong KX, Tariot PN, Mintzer J, Minkwitz MC, Devine NA. Quetiapine to treat agitation in dementia: a randomized, doubleblind, placebo-controlled study. Curr Alzheimer Res 2007; 4(1): 81-93.
20. Golubchik P, Sever J, Weizman A. Low-dose quetiapine for adolescents with autistic spectrum disorder and aggressive behavior: open-label trial. Clin Neuropharmacol 2011; 34(6): 216-219.
21. Mukaddes NM, Abali O. Quetiapine treatment of children and adolescents with Tourette’s disorder. J Ch Adol Psychopharm 2003; 13(3): 295-299.
22. Van den Eynde F, De Saedeleer S, Naudts K, Day J, Vogels C, van Heeringen C, Audenaert K. Quetiapine treatment and improved cognitive functioning in borderline personality disorder. Hum Psychopharmacol 2009; 24(8): 646-649.
23. Van den Eynde F, Senturk V, Naudts K, Vogels C, Bernagie K, Thas O, van Heeringen C, Audenaert K. Efficacy of quetiapine for impulsivity and affective symptoms in borderline personality disorder. J Clin Psychopharmacol 2008; 28(2): 147-155.
24. Adityanjee A, Romine A, Brown E, Thuras P, Lee S, Schulz SC. Quetiapine in patients with borderline personality disorder: an open-label trial. Ann Clin Psychiatry 2008; 20(4): 219-226.
25. Perrella C, Carrus D, Costa E, Schifano F. Quetiapine for the treatment of borderline personality disorder; an open-label study. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31(1): 158-163.
26. Roepke S, Merkl A, Dams A, Ziegenhorn A, Anghelescu IG, Heuser I, Lammers CH. Preliminary evidence of improvement of depressive symptoms but not impulsivity in cluster B personality disorder patients treated with quetiapine: an open label trial. Pharmacopsychiatry 2008; 41(5): 176-181.
27. Rihmer Z. Antidepressive efficacy of quetiapine XR in unipolar major depression – the role of early onset of action and sleepimproving effect in decreasing suicide risk. Neuropsychopharmacol Hung 2009; 11(4): 211-215.
28. Stedman M, Pettinati HM, Brown ES, Kotz M, Calabrese JR, Raines S. A double-blind, placebo-controlled study with quetiapine as adjunct therapy with lithium or divalproex in bipolar I patients with coexisting alcohol dependence. Alcohol Clin Exp Res 2010; 34(10): 1822-1831.
29. Litten RZ, Fertig JB, Falk DE, Ryan ML, Mattson ME, Collins JF, Murtaugh C, Ciraulo D, Green AI, Johnson B, Pettinati H, Swift R, Afshar M, Brunette MF, Tiouririne NA, Kampman K, Stout R. A double-blind, placebo-controlled trial to assess the efficacy of quetiapine fumarate XR in very heavy-drinking alcohol-dependent patients. Alcohol Clin Exp Res 2012; 36(3): 406-416.
30. Cooper ZD, Foltin RW, Hart CL, Vosburg SK, Comer SD, Haney M. A human laboratory study investigating the effects of quetiapine on marijuana withdrawal and relapse in daily marijuana smokers. Addict Biol 2012 Jun 28 [doi: 10.1111/j.1369-1600.2012.00461.x].
31. Kampman KM, Pettinati HM, Lynch KG, Whittingham T, Macfadden W, Dackis C, Tirado C, Oslin DW, Sparkman T, O’Brien CP. A double-blind, placebo-controlled pilot trial of quetiapine for the treatment of Type A and Type B alcoholism. J Clin Psychopharmacol 2007; 27(4): 344-351.